新疆维吾尔族女性乳腺癌与HLA-DRB1基因多态性的关系及临床意义

doi:10.3969/j.issn.1004-616x.2015.05.008

Abstract

Abstract:

OBJECTIVE: To investigate the association of human leukocyte antigen(HLA) DRB1 gene polymorphisms with genetic susceptibility to breast cancer in Uyghur women. METHODS:Genomic DNA was isolated from peripheral blood of 196 patients with breast cancer and 230 healthy Uyghur women, HLA-DRB1 typing was performed by means of polymerase chain reaction-sequence-specific priming (PCR-SSP) and capillary electrophoresis sequencing (CE) method. RESULTS：The frequency of HLA-DRB1*01 genotype in breast cancer was significantly higher than in the control group (χ²=10.180, OR=4.550, P<0.05), while the frequency of HLA-DRB1*16 genotype was significantly lower than in the control group (χ²=4.792, OR=0.492, P<0.05). The frequencies of other HLA-DRB1 alleles did not show statistical significance between the two groups. CONCLUSION:Breast carcinogenesis in Uyghur women was closely associated with the allele polymorphisms of HLA-DRB1, which provides objective evidence for elucidating the molecular mechanism and clinical diagnosis for breast cancer.

Key words: breast cancer, Uyghur women, human leukocyte antigen-DRB1, gene polymorphisms

CLC Number:

R737.9

MUSA·Munire, AIKULA·Gulzaria, HE Chunyu, BAHTIYAR ·Mukaddas. Association and clinical significance of HLA-DRB1 gene polymorphisms with breast carcinogenesis in Uyghur women[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(5): 366-369.

References

[1] 成芳,王晓丽,刘早玲,等. 汉、维吾尔族女性乳腺癌影响因素病例对照研[J]. 中国公共卫生,2010,26(8):948-950.

[2] 徐雅莉,孙强. 乳腺癌高危因素[J]. 肿瘤防治研究,2010,37(10):1201-1212.

[3] 郝桂琴,肖露露. 分子生物学技术在HLA分型中的应用[J]. 中国实验血液学杂志,2002,10(3):268-272.

[4] Zhao S,Yang X,Lu N,et al. The amount of surface HLA-I on T lymphocytes decreases in breast infiltrating ductal carcinoma patients[J]. J Int Med Res,2011,39(2):508-513.

[5] Elliott RL,Jiang XP,Phillips JT,et al. Human leukocyte antigen G expression in breast cancer:role in immunosuppression [J]. Cancer Biother Radiopharm,2011,26(2):153-157.

[6] Karkada M,Welr GM,Quinton T,et al. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses[J]. J Immunother,2010,33(3):250-261.

[7] Seliger B,Ritz U,Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation[J]. Int J Cancer,2006,118:129-138.

[8] Tse KP,Su WH,Chang KP,et al. Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3[J]. Am J Hum Genet,2009,85(2):194-203．

[9] Kubler K,Arndt PF,Wardelmann E,et al．HLA-class II haplotype associations with ovarian cancer[J]. Int J Cancer, 2006,119(12):2980-2985．

[10] Kubler K,Arndt PF,Wardelmann E,et al. Genetic alterations of HLA-class II in ovarian cancer[J]. Int J Cancer,2008,123(6):1350-1356．

[11] 林军,邓长生,孙洁,等. 人类白细胞抗原-DRB1与胃腺癌及其临床特征和幽门螺旋杆菌感染的相关性[J]. 中华消化杂志,2001,3(9):165-167.

[12] 胡建明,陈云昭,刘春,等. HLA-DRB1*01和DQB1* 0602与新疆哈萨克族HPV感染及食管癌发生的相关性研究[J]. 中国肿瘤临床,2010,37(15):857-860.

[13] 潘焕峰,李东复,孙天虹,等. 原发性肝细胞癌与HLA-DRB1*011,31(1):74-80.

[15] Chaudhuri S,Cariappa A,Tang M,et al. Genetic susceptibility to breast cancer:HLA DQB* 03032 and HLA DRB1* 11 may represent protective alleles[J]. Proc Natl Acad Sci USA,2000, 97(21):11451-11454．

[16] Gun FD,Oztruk OG,Polat A. HLA class-II allele frequencies in Turkish breast cancer patients[J]. Med Oncol,2012, 29(2):466-471.

[17] Mahmoodi M,Nahvi H,Mahmoudi M. LA-DRB1,-DQA1 and -DQB1 allele and haplotype frequencies in female patients with early onset breast cancer[J]. Pathol Oncol Res,2012, 18(1):49-55.

[18] David CL,Delia PM,Vernica V. High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer:case-control study[J]. BMC Cancer,2009,9:48.

[19] 黄春芳,程良红,刘远智,等. HLA-DRB1*011,32(7):728-733.

[1]	XIN Yumeng, LIANG Huanxi, YU Yuehua, SUN Zhenxiao. Network pharmacology and molecular docking mechanisms of licorice and dried ginger decoction against breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 7-13.
[2]	ZHAO Yan, SUN Zhenxiao. Metformin inhibitd proliferation and migration of human breast cancer cell in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 35-39.
[3]	FANG Yutong, ZHANG Qunchen, HONG Chaoqun, CHEN Chunfa, CHEN Jiongyu, ZHANG Rendong, WU Jundong. Mechanisms of miR-221 and miR-222 on expression of GATA3 and FOXA1 and their effects in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 435-441,460.
[4]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[5]	CHENG Bin, WANG Xinyu, SUN Yu, ZHANG Jiatai, DONG Shuying. Inhibition of metformin on phthalate-induced proliferation and migration of MCF-7 breast cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 197-202.
[6]	LUO Jiao, ZHANG Kunchi, ZHOU Li. Analysis of differentially expressed microRNAs between the triple negative breast cancer cell line MDA-MB-231 and its brain metastasis cell line [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 218-224.
[7]	LI Weiwei, ZHU Ying. Data mining analyses of expression and prognostic values of the MYB family in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 414-422.
[8]	CHEN Mianling, MA Shuoyi. Regulation of migration and invasion of triple-negative breast cancer cell MDA-MB-231 by miR-21 via targeting PDCD4 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 292-297.
[9]	ZHANG Huijuan, HUANG Dayuan, ZHANG Jie, TANG Haiou, XIE Anxin, TAN Dunyong. Effects of SF1a-PRLR and ΔS2 SF1a-PRLR on proliferation and microRNA expressionin MCF-7 breast cancer cell [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 203-208.
[10]	SUN Quanwu, DU Xiaoping, HAO Jie, SHI Rong, LIU Bo, HUANG Haiyun. β1 integrin expression in breast cancer patients with pathological nipple discharge [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 368-372.
[11]	WANG Lan, ZHANG Yongdong, GUO Hongyun, WANG Tao, WANG Haitao, GUO Huan, YANG Suisheng, LI Xiaoqin, SU Haixiang. Relationships between XRCC3 polymorphisms and breast cancer in northern Chinese women [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 392-396,400.
[12]	DU Juan, HU Xiangyang, LIU Dan, HU Wei, CHEN Tao. Inhibitory effect of total alkaloids of Tougucao on bone metastasis of breast cancer cells in mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(6): 435-441.
[13]	XIAO Hongmei, PAN Tianqi, DONG Shunan, FU Lingmeng, WANG Shaokang, SUN Guiju. Menopausal status on risk for breast cancer from tea consumption: a meta-analysis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 395-399.
[14]	JIANG Pengtao, HU Zhifang, GAO Xingchun, GUO Na, ZHANG Dian, JIANG Fengliang. Involvement of p53 in regulation of DNA damage-induced cell death in MDA-MB-231 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 349-353.
[15]	YANG Shaoyi, ZHANG Qingying, WU Jundong, LIN Qiuqiang, WANG Ruifeng, ZHENG Qingyuan, CAI Fen. Genetic variations in the mitotic checkpoint gene MAD1L1, and risk for breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(3): 209-213.

Association and clinical significance of HLA-DRB1 gene polymorphisms with breast carcinogenesis in Uyghur women

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments